Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$2.36B |
| 2 |
iShares Russell 1000 Growth ETF
IWF
|
+$1.04B |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$951M |
| 4 |
Airbnb
ABNB
|
+$942M |
| 5 |
Kenvue
KVUE
|
+$704M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.7B |
| 2 |
Uber
UBER
|
+$901M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$855M |
| 4 |
Illumina
ILMN
|
+$674M |
| 5 |
iShares Russell 1000 Value ETF
IWD
|
+$637M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.54% |
| 2 | Healthcare | 10.41% |
| 3 | Financials | 10.2% |
| 4 | Consumer Discretionary | 8.92% |
| 5 | Industrials | 6.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
5126
Hyliion Holdings
HYLN
$690M
| $388K | ﹤0.01% |
328,780
-415,651
| -56% | -$622K |
|
|
RSF
5127
RiverNorth Capital and Income Fund
RSF
$58.9M
| $387K | ﹤0.01% |
25,901
+101
| +0.4% | +$1.53K |
|
5128
MediaAlpha
MAX
$821M
| $386K | ﹤0.01% |
46,684
-57,441
| -55% | -$513K |
|
5129
PGIM Floating Rate Income ETF
PFRL
$125M
| $385K | ﹤0.01% |
+7,637
| New | +$385K |
|
5130
Hagerty
HGTY
$1.39B
| $385K | ﹤0.01% |
47,137
+8,083
| +21% | +$70.9K |
|
5131
Invesco Bloomberg Analyst Rating Improvers ETF
UPGD
$121M
| $380K | ﹤0.01% |
6,827
-165
| -2% | -$9.64K |
|
5132
AXT Inc
AXTI
$5.8B
| $380K | ﹤0.01% |
158,381
-84,420
| -35% | -$223K |
|
|
MRNS
5133
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $380K | ﹤0.01% |
47,147
-51,624
| -52% | -$429K |
|
5134
BNY Mellon US Small Cap Core Equity ETF
BKSE
$90M
| $379K | ﹤0.01% |
13,971
-61,755
| -82% | -$1.76M |
|
5135
Schwab 1000 Index ETF
SCHK
$5.94B
| $379K | ﹤0.01% |
18,328
-186
| -1% | -$4K |
|
5136
Duluth Holdings
DLTH
$159M
| $378K | ﹤0.01% |
62,814
-12,493
| -17% | -$83.2K |
|
5137
The ONE Group
STKS
$53M
| $377K | ﹤0.01% |
68,582
+2,165
| +3% | +$14.7K |
|
5138
Northeast Community Bancorp
NECB
$367M
| $377K | ﹤0.01% |
25,548
-22,122
| -46% | -$347K |
|
5139
Invesco S&P Spin-Off ETF
CSD
$228M
| $375K | ﹤0.01% |
6,691
-649
| -9% | -$37.4K |
|
5140
Lyell Immunopharma
LYEL
$360M
| $375K | ﹤0.01% |
12,747
-4,829
| -27% | -$229K |
|
|
NSLR
5141
Neostellar Capital Corp
NSLR
$254M
| $373K | ﹤0.01% |
103,070
+2,758
| +3% | +$10.2K |
|
5142
OptimizeRx
OPRX
$133M
| $372K | ﹤0.01% |
47,766
+20,005
| +72% | +$218K |
|
5143
Ascent Industries
ACNT
$141M
| $372K | ﹤0.01% |
41,885
+8,083
| +24% | +$72.2K |
|
5144
Relmada Therapeutics
RLMD
$527M
| $370K | ﹤0.01% |
123,337
-79,400
| -39% | -$236K |
|
|
HRT
5145
DELISTED
HireRight Holdings Corporation
HRT
| $368K | ﹤0.01% |
38,731
-7,320
| -16% | -$75.5K |
|
5146
Cato Corp
CATO
$66.1M
| $366K | ﹤0.01% |
47,784
-498
| -1% | -$3.97K |
|
5147
Motley Fool 100 Index ETF
TMFC
$2.12B
| $366K | ﹤0.01% |
9,305
+4,376
| +89% | +$179K |
|
|
AFCG
5148
AFC Gamma
AFCG
$63.4M
| $364K | ﹤0.01% |
45,316
-1,554
| -3% | -$13.8K |
|
|
LENZ
5149
LENZ Therapeutics
LENZ
$168M
| $362K | ﹤0.01% |
20,852
+10,578
| +103% | +$184K |
|
5150
Foghorn Therapeutics
FHTX
$360M
| $361K | ﹤0.01% |
72,247
-16,121
| -18% | -$124K |
|
Similar funds
Morgan Stanley's Q3 2023 Portfolio in Review
As of Q3 2023, Morgan Stanley held 7,879 positions worth $983B, down 3.1% from $1.01T the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Morgan Stanley's Q3 2023 filing shows 220 new, 3,247 increased, 3,221 reduced and 253 closed positions. Its largest new stake was TKO Group: 3,583,743 shares worth $301M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $2.7B.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 21% a quarter earlier, followed by Healthcare and Financials.
- Morgan Stanley's largest Q3 2023 buy was TKO Group: 3,583,743 shares worth $301M.
- Morgan Stanley added most to iShares Core S&P 500 ETF in Q3 2023, an estimated $2.36B increase.
- Morgan Stanley's biggest Q3 2023 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $2.7B.
- Morgan Stanley fully exited Magellan Midstream Partners, L.P. in Q3 2023, selling an estimated $432M.
- Morgan Stanley's ten largest holdings make up 18% of its $983B portfolio in Q3 2023.
- Morgan Stanley opened 220 new positions and closed 253 in Q3 2023.
- Morgan Stanley's portfolio value fell 3.1% quarter-over-quarter to $983B.
Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.